دورية أكاديمية
Proteomic and metabolomic characterizations of moyamoya disease patient sera.
| العنوان: | Proteomic and metabolomic characterizations of moyamoya disease patient sera. |
|---|---|
| المؤلفون: | Guo Q; Medical School of Chinese PLA, Beijing, China.; Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Wang QN; Department of Neurosurgery, The Eighth Medical Centre, Chinese PLA General Hospital, Beijing, China., Li J; Medical School of Chinese PLA, Beijing, China.; Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Liu S; Medical School of Chinese PLA, Beijing, China.; Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Wang X; Medical School of Chinese PLA, Beijing, China.; Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Yu D; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Zou ZX; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Gao G; Medical School of Chinese PLA, Beijing, China.; Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Zhang Q; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Hao FB; Medical School of Chinese PLA, Beijing, China.; Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Feng J; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Yang RM; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Wang M; Medical School of Chinese PLA, Beijing, China.; Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China.; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Fu H; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Bao X; Department of Neurosurgery, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China., Duan L; Department of Neurosurgery, The First Medical Centre, Chinese PLA General Hospital, Beijing, China. |
| المصدر: | Brain and behavior [Brain Behav] 2023 Dec; Vol. 13 (12), pp. e3328. Date of Electronic Publication: 2023 Nov 14. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: John Wiley & Sons Country of Publication: United States NLM ID: 101570837 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2162-3279 (Electronic) NLM ISO Abbreviation: Brain Behav Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Hoboken, NJ : John Wiley & Sons |
| مواضيع طبية MeSH: | Moyamoya Disease*, Humans ; Proteomics ; Metabolomics ; Inflammation |
| مستخلص: | Background: The pathogenesis of moyamoya disease (MMD) is unclear. Inflammation and immune imbalance have been identified as potential factors contributing to the occurrence and progression of MMD. However, the specific proteins and metabolites responsible for triggering this process are yet to be established. The purpose of this study is to identify differentially expressed proteins and metabolites in patients with MMD and perform Kyoto Encyclopedia of Genes and Genomes pathway integration analysis to pinpoint crucial proteins and metabolites involved in the disease. Methods: We performed untargeted metabolomic and data-independent acquisition proteomic analyses on the serum samples of individuals with MMD and healthy controls (HC). Results: In patients with MMD versus HC, 24 proteins and 60 metabolites, including 21 anionic metabolites and 39 cationic metabolites, which were significantly different, were identified. In patients with MMD, several proteins involved in inflammation and immune metabolism, such as tubulin beta-6 and complement C4, were found to have significantly altered levels. Similarly, many metabolites involved in inflammation and immune metabolisms, such as dimethyl 4-hydroxyisophthalate, beta-nicotinamide mononucleotide, 2-(3-(4-pyridyl)-1H-1,2,4-triazol-5-yl)pyridine, and PC (17:1/18:2), were significantly altered. Intriguingly, these proteins and metabolites are involved in the progression of atherosclerosis through immune and inflammatory pathways, although some have never been reported in MMD. Moreover, integrated proteomics and metabolomics studies were conducted to determine shared pathways involving cholesterol metabolism, vitamin digestion, fat digestion, and absorption pathways of proteins and metabolites, which warrant further investigation. Conclusions: Significant increases in pro-inflammatory and immunosuppressive abilities have been observed in patients with MMD, accompanied by significant reductions in anti-inflammatory and immune regulation. Various metabolites and proteins implicated in these processes have been identified for the first time. These findings hold immense significance for comprehending the pathogenesis of MMD and for the development of future drug therapies. (© 2023 The Authors. Brain and Behavior published by Wiley Periodicals LLC.) |
| References: | Stroke. 1993 Dec;24(12):1960-7. (PMID: 7902623) FEBS Lett. 2011 Jun 6;585(11):1657-62. (PMID: 21550345) Mol Cell Proteomics. 2015 May;14(5):1400-10. (PMID: 25724911) Pediatr Blood Cancer. 2013 Jul;60(7):1192-7. (PMID: 23509099) Mol Biol Cell. 2014 Jan;25(1):76-86. (PMID: 24173717) Acta Neurochir (Wien). 2000;142(11):1263-73; discussion 1273-4. (PMID: 11201642) Nucleic Acids Res. 2000 Jan 1;28(1):27-30. (PMID: 10592173) Blood. 2016 Apr 21;127(16):1949-53. (PMID: 26929273) Trends Cardiovasc Med. 2016 Aug;26(6):515-23. (PMID: 27079891) Int J Mol Sci. 2022 Apr 19;23(9):. (PMID: 35562882) Radiology. 1995 Jul;196(1):211-8. (PMID: 7784569) J Clin Invest. 1996 Jul 1;98(1):24-9. (PMID: 8690798) Curr Opin Lipidol. 2003 Oct;14(5):421-30. (PMID: 14501580) Curr Pharm Des. 2009;15(1):12-9. (PMID: 19149598) Brain Behav. 2023 Dec;13(12):e3328. (PMID: 37962021) J Neurol Neurosurg Psychiatry. 2008 Aug;79(8):900-4. (PMID: 18077479) Neurol Med Chir (Tokyo). 2022 Apr 15;62(4):165-170. (PMID: 35197402) Cardiovasc Res. 2019 Jul 1;115(9):1393-1407. (PMID: 31095280) Gastroenterology. 1994 Apr;106(4):840-5. (PMID: 8143990) J Hypertens. 2005 Jan;23(1):7-17. (PMID: 15643116) Clin Sci (Lond). 2021 Jun 11;135(11):1389-1408. (PMID: 34086048) J Atheroscler Thromb. 2009;16(6):707-13. (PMID: 19755790) Trends Mol Med. 2022 Nov;28(11):939-950. (PMID: 36115805) Cells. 2019 Nov 04;8(11):. (PMID: 31689891) J Am Coll Cardiol. 2007 Jan 30;49(4):403-14. (PMID: 17258085) Front Immunol. 2021 Jul 14;12:694928. (PMID: 34335607) Acta Neurol Scand. 1994 Oct;90(4):251-5. (PMID: 7839810) Front Immunol. 2022 Aug 04;13:951137. (PMID: 35990657) Stroke. 1983 Jan-Feb;14(1):104-9. (PMID: 6823678) Nutr Rev. 1994 Oct;52(10):327-39. (PMID: 7816350) Stroke. 2005 Oct;36(10):2148-53. (PMID: 16179571) ACS Biomater Sci Eng. 2020 Mar 9;6(3):1614-1629. (PMID: 33455368) Lancet. 1997 Feb 8;349(9049):397. (PMID: 9033468) Ageing Res Rev. 2018 Dec;48:51-78. (PMID: 30273676) Nat Neurosci. 2021 Feb;24(2):214-224. (PMID: 33353966) Medicine (Baltimore). 2016 Mar;95(13):e3186. (PMID: 27043681) Clin Neurol Neurosurg. 1997 Oct;99 Suppl 2:S58-60. (PMID: 9409407) JAMA. 1993 Dec 8;270(22):2693-8. (PMID: 8133587) Ann Clin Lab Sci. 2009 Summer;39(3):219-32. (PMID: 19667406) Toxicol In Vitro. 2004 Jun;18(3):265-9. (PMID: 15046772) J Biol Chem. 2014 Jan 10;289(2):895-908. (PMID: 24275654) Int J Mol Sci. 2018 Jun 27;19(7):. (PMID: 29954107) Nucleic Acids Res. 2009 Jan;37(1):1-13. (PMID: 19033363) J Neurol Sci. 2015 Apr 15;351(1-2):184-186. (PMID: 25743224) Childs Nerv Syst. 2005 May;21(5):358-64. (PMID: 15696334) J Neurosurg. 2004 Feb;100(2 Suppl Pediatrics):142-9. (PMID: 14758941) Indian Heart J. 2000 Nov-Dec;52(7 Suppl):S59-64. (PMID: 11339443) J Neurosurg Sci. 2001 Jun;45(2):83-91. (PMID: 11533532) Circ Res. 2004 Jan 9;94(1):37-45. (PMID: 14656924) J Am Coll Cardiol. 2021 Jun 22;77(24):3031-3041. (PMID: 34140107) Animals (Basel). 2022 May 06;12(9):. (PMID: 35565618) N Engl J Med. 1998 Apr 9;338(15):1042-50. (PMID: 9535670) Lancet Neurol. 2022 Aug;21(8):747-758. (PMID: 35605621) Theranostics. 2020 Apr 27;10(12):5623-5640. (PMID: 32373236) Artif Organs. 2003 Mar;27(3):256-60. (PMID: 12662212) |
| معلومات مُعتمدة: | 82171280 National Natural Science Foundation of China; 82201451 National Natural Science Foundation of China |
| فهرسة مساهمة: | Keywords: integration analysis; metabolome; moyamoya disease; proteome |
| SCR Disease Name: | Moyamoya disease 1 |
| تواريخ الأحداث: | Date Created: 20231114 Date Completed: 20231219 Latest Revision: 20240307 |
| رمز التحديث: | 20240307 |
| مُعرف محوري في PubMed: | PMC10726768 |
| DOI: | 10.1002/brb3.3328 |
| PMID: | 37962021 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2162-3279 |
|---|---|
| DOI: | 10.1002/brb3.3328 |